Abstract: The use of compounds of formula wherein R2, R3, R4, R5, R6 and R7 have several meanings, for the treatment of disorders mediated by protozoan organisms, novel compounds of the above formula and intermediates for the preparation of such compounds, pharmaceutical compositions comprising such novel compounds, a method of treating disorders mediated by protozoan organisms comprising administering such compounds, optionally together with a second drug substance, to a subject in need thereof and the use of such compounds, whenever comprising a photoaffinity label, for the identification of the molecular target(s) of arylamino alcohol antimalarials.

Abstract: The use of compounds of formula wherein R2, R3, R4, R5, R6 and R7 have several meanings, for the treatment of disorders mediated by protozoan organisms, novel compounds of the above formula and intermediates for the preparation of such compounds, pharmaceutical compositions comprising such novel compounds, a method of treating disorders mediated by protozoan organisms comprising administering such compounds, optionally together with a second drug substance, to a subject in need thereof and the use of such compounds, whenever comprising a photoaffinity label, for the identification of the molecular target(s) of arylamino alcohol antimalarials.

Abstract: The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C1-8)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-4)alkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.

Abstract: The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C1-8)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-4)alkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.

Abstract: The invention relates to an assay for identifying an agent that modulates the interaction of a mRNA with a target protein, e.g. HuR and to organic compounds of formula I wherein R1, R2 and R3 are as defined above and their use, e.g. as an inhibitor on the complex-formation of an ARE-containing mRNA and a target protein.

Abstract: 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C3-8)cycloalkyl, (C1-4)alkyl(C3-8)cycloalkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.

Abstract: 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C3-8)cycloalkyl, (C1-4)alkyl(C3-8)cycloalkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.

Abstract: The invention relates to new fluorescent dyes of formula (I) which can be used in high throughput screening both, on the solid phase as well as in homogeneous solution.

Abstract: A compound of formula A—B—D—X—D′—E or formula A—B—D—E—D′—X wherein A is the residue of a solid support, originating from standard materials applied in solid phase and solution phase organic chemistry, B is a linker residue having a group which allows cleavage of a compound of a formula II or a compound of formula III to liberate an D—X—D′—E, or D—E—D′—X fragment, respectively, D and D′ independently of each other are a bond or a spacer residue, E is the residue of a molecule to be investigated produced via combinatorial chemistry, and X is the residue of a fluorescent dye, which is characterized in that a compound of A—B—D—X—D′—E or of formula A—B—D—E—D′—X is tagged by at least one tag residue, and the use of such compounds in the decoding step of a screening process.

Abstract: The invention relates to new fluorescent dyes of formula (I) 1

Abstract: The invention relates to new fluorescent dyes of formula (I) which can be used in high throughput screening both, on the solid phase as well as in homogeneous solution.

Abstract: The invention relates to compounds of formula I ##STR1## wherein the substituents have various significances. They can be prepared by conventional methods, e.g. coupling, substitution, deprotection or protection reactions.They possess interesting pharmacological properties and are thus indicated for use in the treatment of retroviral infections, particularly as HIV proteinase inhibitors.